Giovanna Damia

11PUBLICATIONS
41CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersRadiation therapyPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 26, 2025
Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas.

Federica Guffanti, Ilaria Mengoli, Francesca Ricci

|Jan 25, 2025
Onvansertib and Navitoclax Combination as a New Therapeutic Option for Mucinous Ovarian Carcinoma.

Serena Petrella, Marika Colombo, Mirko Marabese

|Nov 04, 2024
Targeting the DNA damage response in cancer.

Guffanti Federica, Chiappa Michela, Damia Giovanna

|Jul 22, 2024
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas.

Michela Chiappa, Alessandra Decio, Luca Guarrera

|Mar 13, 2024
Different Patterns of Platinum Resistance in Ovarian Cancer Cells with Homologous Recombination Proficient and Deficient Background.

Michela Chiappa, Federica Guffanti, Chiara Grasselli

|Sep 09, 2023
Epithelioid Mesothelioma Patients with Very Long Survival Display Defects in DNA Repair.

Monica Ganzinelli, Federica Guffanti, Anna Ianza

Pageof 2

Frequent Collaborators

5 joint publications

Federica Guffanti

4 joint publications

Michela Chiappa

2 joint publications

V Serra

2 joint publications

A Degasperi